OncoMatch/Clinical Trials/NCT06740019

A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

Is NCT06740019 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JMKX000197 for malignant pleural effusions (mpe).

Phase 1RecruitingJemincareNCT06740019Data as of May 2026

Treatment: JMKX000197 — A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

Check if I qualify

Extracted eligibility criteria

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: STING agonist

Have used interferon gene stimulating factor (STING) agonists for pleural perfusion

Lab requirements

Blood counts

adequate organ function

Kidney function

adequate organ function

Liver function

adequate organ function

Adequate organ function.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify